Seth A. Kaufman, MSHCA, CCRA, is the Sr. Director, Clinical Affairs at Axonics Modulation Technologies. Axonics Modulation Technologies, Inc. (NASDAQ:AXNX) is a medical technology company focused on the design, development, and commercialization of innovative and minimally invasive sacral neuromodulation (“SNM”) solutions. SNM therapy is primarily used to treat patients with overactive bladder (“OAB”), fecal incontinence (“FI”) and urinary retention (“UR”). Axonics currently has marketing approvals in Europe, Canada, and Australia for OAB, FI, and UR. He has 20+ years of life science industry experience focusing on clinical research. He has worked for numerous sponsors as well as consulting for a “Big 4”. He also has past experience with epidemiological research with the US Department of Defense. He has deep knowledge and demonstrated experience with: Good Clinical Practices; ICH; and 21 CFR Parts 50, 54, 56, 312 and 812 as well as established practice with key tools, processes and procedures for clinical operations of many therapeutic areas for complex clinical trials.
Arena’s business-to-business events offer a myriad of opportunities for sponsors and exhibitors to drive their businesses forward.
Our sponsorship packages help companies educate ther target market on key industry issues and spread brand awareness throughout the
If you want to discuss how we can help you generate leads and add-value to your corporate and brand image please contact:
+44 (0)20 7936 6948